Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNM001
MIFTS: 52

Bone Marrow Cancer

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bone Marrow Cancer

About this section

MalaCards integrated aliases for Bone Marrow Cancer:

Name: Bone Marrow Cancer 12 15
Malignant Neoplasm of Bone Marrow 12 73
Chronic Myeloproliferative Disorder 73
Myeloproliferative Disorders 44
Malignant Bone Marrow Tumor 12
Myeloproliferative Disorder 40
Myeloproliferative Disease 73
Bone Marrow Neoplasms 73
Bone Marrow Neoplasm 12
Bone Marrow Tumor 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:4960
ICD10 33 D47.1
MeSH 44 D009196
SNOMED-CT 68 20921005
Sources

Summaries for Bone Marrow Cancer

About this section
Disease Ontology : 12 A hematopoietic cancer that derives from the blood-forming stem cells of the bone marrow.

MalaCards based summary : Bone Marrow Cancer, also known as malignant neoplasm of bone marrow, is related to myeloproliferative neoplasm and juvenile myelomonocytic leukemia. An important gene associated with Bone Marrow Cancer is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Hydroxyurea and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood... more...

Sources

Related Diseases for Bone Marrow Cancer

About this section

Diseases related to Bone Marrow Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 33.1 ABL1 BCR FGFR1 JAK2 KIT MPL
2 juvenile myelomonocytic leukemia 32.6 FLT3 JAK2 PDGFRA PDGFRB PTPN11 RUNX1
3 essential thrombocythemia 32.4 ABL1 BCR CD177 EPO EPOR GATA1
4 polycythemia vera 32.4 ABL1 CD177 EPO EPOR IL3 JAK2
5 leukemia, chronic myeloid 32.3 ABL1 BCR CD177 EPO FGFR1 FLT3
6 thrombocythemia 1 32.1 MPL THPO
7 myelodysplastic myeloproliferative cancer 31.9 ABL1 JAK2 PTPN11
8 myelofibrosis 31.9 CD177 EPO FLT3 GATA1 IL3 JAK2
9 myelodysplastic syndrome 31.7 ABL1 EPO EPOR FLT3 GATA1 IL3
10 leukemia 31.2 ABL1 BCR FLT3 JAK2 KIT MPL
11 thrombocytosis 31.2 EPO IL3 JAK2 MPL THPO
12 megakaryocytic leukemia 30.9 GATA1 IL3 JAK2 RUNX1 THPO
13 myeloid leukemia 30.8 ABL1 BCR FLT3 IL3 JAK2 KIT
14 polycythemia 30.8 CD177 EPO EPOR IL3 JAK2 MPL
15 splenomegaly 30.7 EPO JAK2 MPL
16 mastocytosis 30.7 KIT PDGFRA PDGFRB
17 acute leukemia 30.6 FLT3 IL3 JAK2 KIT RUNX1
18 chronic myelomonocytic leukemia 30.5 FLT3 JAK2 KIT PDGFRB PTPN11 RUNX1
19 hypereosinophilic syndrome 30.4 ABL1 FGFR1 IL3 KIT PDGFRA PDGFRB
20 leukemia, acute myeloid 30.4 ABL1 BCR FLT3 GATA1 IL3 JAK2
21 systemic mastocytosis 30.4 FGFR1 JAK2 KIT PDGFRA PDGFRB
22 leukemia, acute lymphoblastic 30.3 ABL1 BCR FLT3 MIR155 RUNX1
23 acquired polycythemia 30.2 EPO EPOR JAK2
24 pancytopenia 30.2 EPO IL3 MPL THPO
25 myeloma, multiple 30.1 EPO FGFR3 JAK2 KIT PTPN11
26 myeloproliferative disorder, chronic, with eosinophilia 12.6
27 pdgfrb-associated chronic eosinophilic leukemia 11.7
28 budd-chiari syndrome 11.3
29 noonan syndrome 1 11.3
30 erythromelalgia 11.3
31 campomelic dysplasia 11.1
32 mastocytosis, cutaneous 11.1
33 nodular regenerative hyperplasia 11.1
34 ocular cancer 11.0
35 papular mucinosis 11.0
36 erythermalgia, primary 10.9
37 thrombocythemia 2 10.9
38 noonan syndrome 3 10.9
39 noonan syndrome 4 10.9
40 noonan syndrome 5 10.9
41 noonan syndrome 6 10.9
42 chromosome 8p11 myeloproliferative syndrome 10.9
43 noonan syndrome 7 10.9
44 thrombocythemia 3 10.9
45 noonan syndrome 8 10.9
46 noonan syndrome 9 10.9
47 noonan syndrome 10 10.9
48 down syndrome 10.7
49 thrombosis 10.5
50 subacute myeloid leukemia 10.4 FLT3 JAK2

Graphical network of the top 20 diseases related to Bone Marrow Cancer:



Diseases related to Bone Marrow Cancer
Sources

Symptoms & Phenotypes for Bone Marrow Cancer

About this section

GenomeRNAi Phenotypes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.38 BCR
2 Decreased viability GR00173-A 10.38 FLT3 PDGFRA
3 Decreased viability GR00221-A-1 10.38 ABL1 FGFR1 FGFR3 FLT3 KIT PDGFRA
4 Decreased viability GR00221-A-2 10.38 ABL1 BCR FGFR1 FGFR3 JAK2
5 Decreased viability GR00221-A-3 10.38 ABL1 FGFR3 PDGFRA PDGFRB
6 Decreased viability GR00221-A-4 10.38 BCR FLT3 PDGFRA PDGFRB
7 Decreased viability GR00301-A 10.38 BCR KIT
8 Decreased viability GR00342-S-1 10.38 ABL1 PDGFRB
9 Decreased viability GR00342-S-2 10.38 ABL1
10 Decreased viability GR00342-S-3 10.38 ABL1 BCR
11 Decreased viability GR00402-S-2 10.38 ABL1 BCR FGFR1 FGFR3 JAK2 FLT3
12 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
13 Decreased substrate adherent cell growth GR00193-A-2 9.7 ABL1 KIT
14 Decreased substrate adherent cell growth GR00193-A-4 9.7 ABL1 FGFR1 FLT3 KIT
15 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.65 ABL1 FGFR1 FGFR3 FLT3 PDGFRB
16 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.8 FGFR3 FLT3 KIT

MGI Mouse Phenotypes related to Bone Marrow Cancer:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 ABL1 BCR EPO EPOR FGFR1 FGFR3
2 hematopoietic system MP:0005397 10.44 ABL1 BCR CD177 EPO EPOR FGFR1
3 immune system MP:0005387 10.41 ABL1 BCR CD177 EPO EPOR FGFR1
4 homeostasis/metabolism MP:0005376 10.4 ABL1 BCR EPO EPOR FGFR1 FGFR3
5 growth/size/body region MP:0005378 10.37 ABL1 BCR EPOR FGFR1 FGFR3 FLT3
6 embryo MP:0005380 10.33 ABL1 EPO EPOR FGFR1 GATA1 JAK2
7 cardiovascular system MP:0005385 10.28 ABL1 EPO EPOR FGFR1 GATA1 KIT
8 mortality/aging MP:0010768 10.27 ABL1 BCR EPO EPOR FGFR1 FGFR3
9 endocrine/exocrine gland MP:0005379 10.19 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
10 digestive/alimentary MP:0005381 10.16 ABL1 BCR FGFR1 FGFR3 KIT PDGFRA
11 integument MP:0010771 10.16 EPO FGFR1 FGFR3 GATA1 JAK2 KIT
12 craniofacial MP:0005382 10.11 ABL1 FGFR1 FGFR3 KIT PDGFRA PDGFRB
13 liver/biliary system MP:0005370 10.06 ABL1 BCR EPO EPOR GATA1 JAK2
14 limbs/digits/tail MP:0005371 9.98 EPO FGFR1 FGFR3 KIT PDGFRA PDGFRB
15 normal MP:0002873 9.97 ABL1 BCR EPO EPOR FGFR1 FGFR3
16 neoplasm MP:0002006 9.87 FGFR3 FLT3 JAK2 KIT PDGFRA PTPN11
17 no phenotypic analysis MP:0003012 9.86 EPOR FGFR1 FGFR3 FLT3 KIT PDGFRA
18 respiratory system MP:0005388 9.61 ABL1 EPO EPOR FGFR3 GATA1 KIT
19 skeleton MP:0005390 9.4 ABL1 EPO FGFR1 FGFR3 FLT3 GATA1
Sources

Drugs & Therapeutics for Bone Marrow Cancer

About this section

Drugs for Bone Marrow Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
2
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
3
Iron Approved Phase 3 7439-89-6 23925
4
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
5
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
6 Pomalidomide Approved Phase 3,Phase 2,Phase 1 19171-19-8
7
Anagrelide Approved Phase 3,Phase 2 68475-42-3 2182
8
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
9 tannic acid Approved Phase 3,Phase 1,Phase 2
10
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2 94-09-7, 1994-09-7 2337
11
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2 147-94-4 6253
12
Melphalan Approved Phase 3,Phase 2,Not Applicable 148-82-3 4053 460612
13
Danazol Approved Phase 3 17230-88-5 28417
14 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
15 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
16 interferons Phase 3,Phase 2,Phase 1
17 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
18 proline Phase 3,Phase 1,Phase 2
19 Interferon-alpha Phase 3,Phase 2,Phase 1
20 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
21 Analgesics Phase 3,Phase 2,Phase 1
22 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
23 Fibrinolytic Agents Phase 3,Phase 2
24 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
25 Anti-Inflammatory Agents Phase 3,Phase 2
26 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Not Applicable
27 Cyclooxygenase Inhibitors Phase 3,Phase 2
28 Platelet Aggregation Inhibitors Phase 3,Phase 2
29 Antipyretics Phase 3,Phase 2
30 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
32 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
33 Mitogens Phase 3,Not Applicable
34 glucocorticoids Phase 3,Phase 2
35 Androgens Phase 3
36 6-Mercaptopurine Phase 3
37
Panobinostat Approved, Investigational Phase 1, Phase 2,Phase 2 404950-80-7 6918837
38
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
39
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
40
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2,Not Applicable 22916-47-8 4189
41
Arsenic trioxide Approved, Investigational Phase 2,Phase 1 1327-53-3 518740
42
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
43
Zoledronic acid Approved Phase 2 118072-93-8 68740
44
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
45
alemtuzumab Approved, Investigational Phase 2 216503-57-0
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
48
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
49 Mirabegron Approved Phase 2 223673-61-8
50
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
2 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
3 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Completed NCT02292446 Phase 3 Ruxolitinib
4 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
5 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
6 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
7 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Completed NCT01243944 Phase 3 ruxolitinib tablets
8 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
9 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
10 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
11 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
12 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
13 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
14 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
15 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
16 The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation Not yet recruiting NCT03640325 Phase 3
17 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Not yet recruiting NCT03755518 Phase 3 FEDRATINIB
18 Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Terminated NCT01645124 Phase 3 Hydroxyurea
19 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
20 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
21 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
22 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
23 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
24 Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers Completed NCT00421213 Phase 2 Darinaparsin
25 The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) Completed NCT00436059 Phase 2 bortezomib
26 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Completed NCT01193283 Phase 1, Phase 2 Cyclophosphamide;Cyclosporine
27 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector Completed NCT01428128 Phase 2 Arsenic Trioxide
28 SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. Completed NCT00113893 Phase 2 SCIO-469;SCIO-469;SCIO-469;SCIO-469
29 Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers Completed NCT01367288 Phase 2 Zometa + Neoadjuvant therapy;Neoadjuvant therapy
30 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
31 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
32 Velcade Consolidation Bone Study Completed NCT01286077 Phase 2 bortezomib
33 Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD Completed NCT00908232 Phase 2 Cyclophosphamide;Bortezomib;Dexamethasone;Lenalidomide
34 Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) Completed NCT01745640 Phase 2 POMALIDOMIDE;Dexamethasone
35 Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia Completed NCT00936117 Phase 2 Posaconazole
36 IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma Completed NCT01053949 Phase 2 Pomalidomide;Pomalidomide
37 A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera Completed NCT01901432 Phase 1, Phase 2 Givinostat
38 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia Completed NCT01420783 Phase 2 SAR302503
39 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
40 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
41 Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Completed NCT01193699 Phase 1, Phase 2 PEG-P-INF alpha-2b (P1101)
42 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Completed NCT02311569 Phase 2 Mirabegron
43 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2 Gleevec
44 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Completed NCT00928707 Phase 2 GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
45 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
46 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT02515630 Phase 2 MMB
47 Effects of Imatinib Mesylate in Polycythemia Vera Completed NCT00430066 Phase 2 Imatinib Mesylate
48 Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Completed NCT01348490 Phase 2 Ruxolitinib (INCB018424)
49 Study of SB939 in Subjects With Myelofibrosis Completed NCT01200498 Phase 2 SB939
50 Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia Completed NCT02124746 Phase 2 Momelotinib

Search NIH Clinical Center for Bone Marrow Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: myeloproliferative disorders

Sources

Genetic Tests for Bone Marrow Cancer

About this section
Sources

Anatomical Context for Bone Marrow Cancer

About this section

MalaCards organs/tissues related to Bone Marrow Cancer:

41
Bone, Bone Marrow, Myeloid, Liver, T Cells, B Cells
Sources

Publications for Bone Marrow Cancer

About this section

Articles related to Bone Marrow Cancer:

# Title Authors Year
1
Mayo breakthrough: virus may destroy bone marrow cancer. ( 25233543 )
2014
2
Erythrokinetics and androgens in bone marrow cancer. ( 975001 )
1976
Sources

Variations for Bone Marrow Cancer

About this section

ClinVar genetic disease variations for Bone Marrow Cancer:

6 (show all 14)
# Gene Variation Type Significance SNP ID Assembly Location
1 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
2 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh38 Chromosome 9, 5073770: 5073770
3 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
4 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic rs121913485 GRCh38 Chromosome 4, 1804372: 1804372
5 INSL6; JAK2 NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly) single nucleotide variant Pathogenic/Likely pathogenic rs1057519721 GRCh37 Chromosome 9, 5078360: 5078360
6 INSL6; JAK2 NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly) single nucleotide variant Pathogenic/Likely pathogenic rs1057519721 GRCh38 Chromosome 9, 5078360: 5078360
7 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh37 Chromosome 5, 149441328: 149441328
8 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh38 Chromosome 5, 150061765: 150061765
9 FGFR3 NM_001163213.1(FGFR3): c.1663G> A (p.Val555Met) single nucleotide variant Likely pathogenic rs199544087 GRCh37 Chromosome 4, 1807488: 1807488
10 FGFR3 NM_001163213.1(FGFR3): c.1663G> A (p.Val555Met) single nucleotide variant Likely pathogenic rs199544087 GRCh38 Chromosome 4, 1805761: 1805761
11 INSL6; JAK2 NM_004972.3(JAK2): c.2624C> A (p.Thr875Asn) single nucleotide variant Likely pathogenic rs1057520016 GRCh37 Chromosome 9, 5089726: 5089726
12 INSL6; JAK2 NM_004972.3(JAK2): c.2624C> A (p.Thr875Asn) single nucleotide variant Likely pathogenic rs1057520016 GRCh38 Chromosome 9, 5089726: 5089726
13 INSL6; JAK2 NM_004972.3(JAK2): c.1691G> T (p.Arg564Leu) single nucleotide variant Likely pathogenic rs368927897 GRCh37 Chromosome 9, 5072541: 5072541
14 INSL6; JAK2 NM_004972.3(JAK2): c.1691G> T (p.Arg564Leu) single nucleotide variant Likely pathogenic rs368927897 GRCh38 Chromosome 9, 5072541: 5072541
Sources

Expression for Bone Marrow Cancer

About this section
Search GEO for disease gene expression data for Bone Marrow Cancer.
Sources

Pathways for Bone Marrow Cancer

About this section

Pathways related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.06 ABL1 CD177 FGFR1 FGFR3 FLT3 IL3
2
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 13.9 ABL1 EPOR FGFR1 FGFR3 IL3 KIT
3
ERK Signaling 64
Show member pathways
 13.9 ABL1 EPOR FGFR1 FGFR3 FLT3 IL3
4
GPCR Pathway 64
Show member pathways
 13.77 EPOR FGFR1 FGFR3 FLT3 IL3 JAK2
5
HIV Life Cycle 66
Show member pathways
 13.74 BCR FGFR1 FGFR3 JAK2 KIT PDGFRA
6
PEDF Induced Signaling 64
Show member pathways
 13.7 EPO EPOR FGFR1 FGFR3 FLT3 IL3
7
Activation of cAMP-Dependent PKA 64
Show member pathways
 13.6 EPOR FGFR1 FGFR3 FLT3 IL3 KIT
8
Developmental Biology 66
Show member pathways
 13.54 ABL1 FGFR1 FGFR3 IL3 JAK2 KIT
9
TGF-Beta Pathway 64
Show member pathways
 13.51 EPO EPOR FGFR1 FGFR3 FLT3 IL3
10
Akt Signaling 64
Show member pathways
 13.44 EPOR FGFR1 FGFR3 FLT3 IL3 JAK2
11
Cytokine Signaling in Immune system 66
Show member pathways
 13.41 FGFR1 FGFR3 FLT3 IL3 JAK2 KIT
12
CREB Pathway 64
Show member pathways
 13.37 EPOR FGFR1 FGFR3 FLT3 IL3 KIT
13
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.36 ABL1 CD177 GATA1 IL3 JAK2 MPL
14
PAK Pathway 64
Show member pathways
 13.35 FGFR1 FGFR3 IL3 JAK2 KIT PDGFRA
15
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.33 EPOR FGFR1 FGFR3 FLT3 IL3 KIT
16
PI3K/AKT activation 66
Show member pathways
 13.13 FGFR1 FGFR3 KIT PDGFRA PDGFRB PTPN11
17
Phospholipase-C Pathway 64
Show member pathways
 13.11 FGFR1 FGFR3 IL3 KIT PDGFRA PDGFRB
18
p70S6K Signaling 64
Show member pathways
 13.1 FGFR1 FGFR3 IL3 JAK2 KIT PDGFRA
19
Actin Nucleation by ARP-WASP Complex 64
Show member pathways
 13.04 EPOR FGFR1 FGFR3 FLT3 KIT PDGFRA
20
Development Angiotensin activation of ERK 22
Show member pathways
 12.95 EPO EPOR JAK2 KIT PDGFRA PDGFRB
21
PI3K-Akt signaling pathway 37
Show member pathways
 12.94 EPO EPOR FGFR1 FGFR3 FLT3 IL3
22
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.91 EPOR FGFR1 FGFR3 JAK2 PDGFRA PDGFRB
23
MAPK signaling pathway 37 1
12.82 FGFR1 FGFR3 FLT3 KIT PDGFRA PDGFRB
24
Ras signaling pathway 37
Show member pathways
 12.79 ABL1 FGFR1 FGFR3 FLT3 KIT PDGFRA
25
Glioma 37
Show member pathways
 12.78 FGFR1 FGFR3 JAK2 PDGFRA PDGFRB
26
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.78 FGFR1 FGFR3 KIT PDGFRA PDGFRB PTPN11
27
Endometrial cancer 37
Show member pathways
 12.77 ABL1 BCR FGFR1 FLT3 IL3 KIT
28
NF-kappaB Signaling 4
12.63 GATA1 IL3 JAK2 KIT MPL RUNX1
29
MicroRNAs in cancer 37
12.57 ABL1 FGFR3 MIR155 PDGFRA PDGFRB
30
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.5 FGFR1 FGFR3 PDGFRA PDGFRB
31
Development FGFR signaling pathway 22
Show member pathways
 12.45 FGFR1 FGFR3 FLT3 PTPN11
32
Apoptosis Pathway 72
Show member pathways
 12.45 FGFR1 FGFR3 PDGFRA PDGFRB
33
Phospholipase D signaling pathway 37
Show member pathways
 12.42 KIT PDGFRA PDGFRB PTPN11
34
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.38 EPOR FGFR1 FGFR3 FLT3 IL3 KIT
35
Kit receptor signaling pathway 1
Show member pathways
 12.24 EPO EPOR IL3 JAK2 KIT PTPN11
36
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.22 FGFR1 FGFR3 PDGFRA PDGFRB
37
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.22 ABL1 EPO EPOR IL3 JAK2 MPL
38
Signaling by FGFR2 in disease 66
Show member pathways
 12.2 BCR FGFR1 FGFR3 ZMYM2
39
AKT Signaling Pathway 67
12.17 FGFR1 FGFR3 PDGFRA PDGFRB
40
Pathways in cancer 37
12.16 ABL1 BCR EPO EPOR FGFR1 FGFR3
41
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.14 FGFR1 FGFR3 IL3 JAK2 PTPN11 THPO
42
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.13 GATA1 IL3 PDGFRB RUNX1 THPO
43
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.12 ABL1 FGFR1 FGFR3 IL3 KIT PDGFRA
44
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.07 EPO FLT3 IL3 KIT MPL THPO
45
Visual Cycle in Retinal Rods 64
11.96 JAK2 MPL PTPN11 THPO
46
Development EPO-induced Jak-STAT pathway 22
Show member pathways
 11.96 EPO EPOR JAK2 PTPN11
47
Jak-Stat Signaling Pathway (sino) 67
11.96 ABL1 EPO EPOR IL3 JAK2 PTPN11
48
Hematopoietic cell lineage 37
11.94 EPO EPOR FLT3 IL3 KIT THPO
49
Angiogenesis (CST) 4
11.91 FGFR1 FGFR3 PDGFRA PDGFRB
50
VEGF Pathway (Tocris) 61
Show member pathways
 11.87 FGFR1 FLT3 KIT PDGFRB
Sources

GO Terms for Bone Marrow Cancer

About this section

Cellular components related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.63 EPO FGFR3 KIT MPL PDGFRA PDGFRB
2 integral component of plasma membrane GO:0005887 9.56 EPOR FGFR1 FGFR3 FLT3 KIT MPL
3 receptor complex GO:0043235 9.1 FGFR1 FGFR3 FLT3 KIT PDGFRA PDGFRB

Biological processes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.99 BCR EPOR FGFR1 PTPN11
2 positive regulation of cell migration GO:0030335 9.99 JAK2 KIT PDGFRA PDGFRB
3 phosphatidylinositol phosphorylation GO:0046854 9.97 FGFR1 FGFR3 KIT PDGFRA PDGFRB PTPN11
4 MAPK cascade GO:0000165 9.97 FGFR1 FGFR3 FLT3 IL3 JAK2 KIT
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.93 FLT3 KIT PDGFRA PDGFRB
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.92 ABL1 GATA1 IL3 JAK2
7 positive regulation of MAP kinase activity GO:0043406 9.91 FGFR1 FLT3 KIT PDGFRB
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.91 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
9 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.9 FGFR1 FGFR3 FLT3 PTPN11
10 male gonad development GO:0008584 9.89 GATA1 KIT PDGFRB
11 erythrocyte differentiation GO:0030218 9.89 EPO GATA1 JAK2 KIT
12 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.88 FGFR3 FLT3 KIT PDGFRA PDGFRB
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 EPO FGFR3 FLT3 IL3 JAK2 KIT
14 cell chemotaxis GO:0060326 9.87 KIT PDGFRA PDGFRB
15 fibroblast growth factor receptor signaling pathway GO:0008543 9.87 FGFR1 FGFR3 PTPN11
16 hemopoiesis GO:0030097 9.86 FLT3 KIT RUNX1
17 positive regulation of fibroblast proliferation GO:0048146 9.84 MIR155 PDGFRA PDGFRB
18 phosphatidylinositol-mediated signaling GO:0048015 9.83 FGFR1 PDGFRA PDGFRB
19 platelet aggregation GO:0070527 9.83 GATA1 MPL PDGFRA
20 positive regulation of phospholipase C activity GO:0010863 9.81 FGFR1 KIT PDGFRA PDGFRB
21 protein autophosphorylation GO:0046777 9.81 ABL1 BCR FGFR1 FGFR3 FLT3 JAK2
22 regulation of hematopoietic stem cell differentiation GO:1902036 9.8 ABL1 GATA1 RUNX1
23 embryonic hemopoiesis GO:0035162 9.79 GATA1 IL3 KIT
24 erythropoietin-mediated signaling pathway GO:0038162 9.75 EPO EPOR KIT
25 platelet-derived growth factor receptor signaling pathway GO:0048008 9.73 ABL1 BCR JAK2 PDGFRA PDGFRB PTPN11
26 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.71 JAK2 PDGFRB
27 interleukin-6-mediated signaling pathway GO:0070102 9.71 JAK2 PTPN11
28 megakaryocyte development GO:0035855 9.71 KIT PTPN11
29 negative regulation of cell-cell adhesion GO:0022408 9.71 ABL1 JAK2
30 cellular response to thyroid hormone stimulus GO:0097067 9.7 GATA1 KIT
31 response to hyperoxia GO:0055093 9.7 EPO PDGFRB
32 dendritic cell differentiation GO:0097028 9.7 FLT3 GATA1
33 positive regulation of osteoblast proliferation GO:0033690 9.68 ABL1 GATA1
34 Bergmann glial cell differentiation GO:0060020 9.68 ABL1 PTPN11
35 positive regulation of phospholipase activity GO:0010518 9.68 FGFR1 FGFR3
36 regulation of cytokine-mediated signaling pathway GO:0001959 9.67 IL3 RUNX1
37 retina vasculature development in camera-type eye GO:0061298 9.67 PDGFRA PDGFRB
38 myeloid progenitor cell differentiation GO:0002318 9.67 FLT3 KIT
39 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.65 ABL1 PDGFRB
40 thrombopoietin-mediated signaling pathway GO:0038163 9.65 MPL THPO
41 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.65 ABL1 EPO FGFR1 FGFR3 FLT3 KIT
42 metanephric glomerular capillary formation GO:0072277 9.64 PDGFRA PDGFRB
43 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.64 PDGFRA PDGFRB
44 peptidyl-tyrosine phosphorylation GO:0018108 9.36 ABL1 BCR FGFR1 FGFR3 FLT3 IL3
45 cell differentiation GO:0030154 10.22 ABL1 FGFR1 FGFR3 FLT3 JAK2 KIT
46 phosphorylation GO:0016310 10.21 ABL1 BCR FGFR1 FGFR3 FLT3 JAK2
47 negative regulation of apoptotic process GO:0043066 10.19 EPO FGFR1 FGFR3 FLT3 GATA1 KIT
48 protein phosphorylation GO:0006468 10.19 ABL1 BCR FGFR1 FGFR3 FLT3 JAK2
49 cytokine-mediated signaling pathway GO:0019221 10.11 EPOR FLT3 IL3 JAK2 KIT MPL
50 positive regulation of MAPK cascade GO:0043410 10.02 FGFR1 FGFR3 FLT3 KIT PDGFRA PDGFRB

Molecular functions related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.98 FGFR1 FGFR3 FLT3 JAK2 KIT PDGFRA
2 transmembrane signaling receptor activity GO:0004888 9.87 FGFR1 FGFR3 FLT3 KIT MPL PDGFRA
3 1-phosphatidylinositol-3-kinase activity GO:0016303 9.76 FGFR1 FGFR3 FLT3 PTPN11
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.73 FGFR1 FGFR3 KIT PDGFRA PDGFRB PTPN11
5 cytokine receptor activity GO:0004896 9.69 EPOR FLT3 MPL
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 FGFR1 FGFR3 FLT3 KIT PDGFRA PDGFRB
7 platelet-derived growth factor receptor binding GO:0005161 9.59 PDGFRA PDGFRB
8 insulin receptor substrate binding GO:0043560 9.58 JAK2 PTPN11
9 platelet-derived growth factor binding GO:0048407 9.58 PDGFRA PDGFRB
10 peptide hormone receptor binding GO:0051428 9.57 JAK2 PTPN11
11 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.56 FGFR1 FGFR3 FLT3 IL3 JAK2 KIT
12 vascular endothelial growth factor-activated receptor activity GO:0005021 9.55 FLT3 PDGFRA
13 fibroblast growth factor-activated receptor activity GO:0005007 9.54 FGFR1 FGFR3
14 vascular endothelial growth factor binding GO:0038085 9.52 PDGFRA PDGFRB
15 protein tyrosine kinase activity GO:0004713 9.36 ABL1 BCR FGFR1 FGFR3 FLT3 IL3
16 protein binding GO:0005515 10.49 ABL1 BCR CD177 EPO EPOR FGFR1
17 ATP binding GO:0005524 10.18 ABL1 BCR FGFR1 FGFR3 FLT3 JAK2
18 transferase activity GO:0016740 10.15 ABL1 BCR FGFR1 FGFR3 FLT3 JAK2
19 kinase activity GO:0016301 10.02 ABL1 BCR FGFR1 FGFR3 FLT3 JAK2
20 protein kinase activity GO:0004672 10.01 ABL1 FGFR1 FGFR3 FLT3 JAK2 KIT
Sources

Sources for Bone Marrow Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....